Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

Company Overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Key Stats

• Today's Range: $28.49 to $29.04
• 50-Day Range: $26.31 to $41.44
• 52-Week Range: $25.81 to $60.37
• Volume: 1.26 million shs
• Average Volume: 2.24 million shs
• Market Capitalization: $2.80 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $81.50
• Consensus Rating: Moderate Buy

Ultragenyx Pharmaceutical Stock Analysis - MarketRank™

Ultragenyx Pharmaceutical scored higher than 93% of companies evaluated by MarketBeat, and ranked 80th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ultragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Ultragenyx Pharmaceutical has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($5.18) to ($3.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ultragenyx Pharmaceutical is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ultragenyx Pharmaceutical is -5.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ultragenyx Pharmaceutical has a P/B Ratio of 18.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.39% of the float of Ultragenyx Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Ultragenyx Pharmaceutical has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Ultragenyx Pharmaceutical has recently decreased by 13.18%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ultragenyx Pharmaceutical does not currently pay a dividend.

Dividend Growth

Ultragenyx Pharmaceutical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.8 / 5
• Environmental Score: -2.28

Percentage of Shares Shorted

8.39% of the float of Ultragenyx Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Ultragenyx Pharmaceutical has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Ultragenyx Pharmaceutical has recently decreased by 13.18%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.26

News Sentiment

Ultragenyx Pharmaceutical has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 48 news articles for Ultragenyx Pharmaceutical this week, compared to 10 articles on an average week.

Search Interest

16 people have searched for RARE on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

11 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $89,923.00 in company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Ultragenyx Pharmaceutical is held by insiders.

Percentage Held by Institutions

97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RARE Stock Analysis - Frequently Asked Questions

How have RARE shares performed this year?

Ultragenyx Pharmaceutical's stock was trading at $42.07 at the beginning of 2025. Since then, RARE stock has decreased by 31.0% and is now trading at $29.01.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) released its quarterly earnings data on Tuesday, August, 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical's revenue was up 13.2% compared to the same quarter last year.
Read the conference call transcript.

Who are Ultragenyx Pharmaceutical's major shareholders?

Top institutional shareholders of Ultragenyx Pharmaceutical include Sands Capital Management LLC (4.09%), State Street Corp (2.67%), Federated Hermes Inc. (2.13%) and Geode Capital Management LLC (1.81%). Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, John Richard Pinion, Howard Horn, Dennis Karl Huang, Eric Crombez, Mardi Dier, Karah Herdman Parschauer, Erik Harris, Theodore Alan Huizenga, Camille L Bedrosian, Corazon (Corsee) D Sanders and Matthew K Fust.
View institutional ownership trends.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 8/05/2025
• Today: 8/14/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RARE
• CIK: 1515673
• Web: www.ultragenyx.com
• Phone: (415) 483-8800
• Fax: 415-483-8810
• Employees: 1,294
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Ultragenyx Pharmaceutical: $81.50
• High Price Target: $128.00
• Low Price Target: $34.00
• Potential Upside/Downside: +180.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.92
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$569.18 million
• Net Margins: -87.34%
• Pretax Margin: -86.93%
• Return on Equity: -237.48%
• Return on Assets: -37.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.45
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $560.23 million
• Price / Sales: 4.99
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.57 per share
• Price / Book: 18.48

Miscellaneous

• Outstanding Shares: 96,370,000
• Free Float: 91,072,000
• Market Cap: $2.80 billion
• Optionable: Optionable
• Beta: 0.25